At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study - Summary - MDSpire
Advertisement
Telehealth-Enabled Subcutaneous Ketamine Treatment at Home: Evaluating Safety, Feasibility, and Clinical Outcomes in Adults with Moderate to Severe Depression, Anxiety, or PTSD in a Diverse U.S. Cohort - A Retrospective Study
To evaluate the safety, feasibility, and clinical outcomes of telehealth-enabled subcutaneous ketamine treatment at home for adults with moderate to severe depression, anxiety, or PTSD.
Approach:
Study Design: A retrospective study assessing the outcomes of telehealth-enabled subcutaneous ketamine treatment.
Population: Diverse U.S. cohort of adults diagnosed with moderate to severe depression, anxiety, or PTSD.
Key Findings:
Telehealth-enabled ketamine treatment was found to be safe and feasible for home administration.
Clinical outcomes indicated improvements in symptoms of depression, anxiety, and PTSD among participants.
Interpretation:
Limitations:
Retrospective design may limit the ability to establish causality.
Potential selection bias in the cohort may affect generalizability.